Browse > Article
http://dx.doi.org/10.4062/biomolther.2021.195

Characterization of KRC-108 as a TrkA Kinase Inhibitor with Anti-Tumor Effects  

Lee, Hyo Jeong (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University)
Moon, Yeongyu (Gyeongnam Biohealth Research Center, Gyeongnam Branch Institute, Korea Institute of Toxicology)
Choi, Jungil (Gyeongnam Biohealth Research Center, Gyeongnam Branch Institute, Korea Institute of Toxicology)
Heo, Jeong Doo (Gyeongnam Biohealth Research Center, Gyeongnam Branch Institute, Korea Institute of Toxicology)
Kim, Sekwang (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University)
Nallapaneni, Hari Krishna (College of Pharmacy, Kangwon National University)
Chin, Young-Won (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Seoul National University)
Lee, Jongkook (College of Pharmacy, Kangwon National University)
Han, Sun-Young (College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University)
Publication Information
Biomolecules & Therapeutics / v.30, no.4, 2022 , pp. 360-367 More about this Journal
Abstract
Tropomyosin receptor kinase A (TrkA) protein is a receptor tyrosine kinase encoded by the NTRK1 gene. TrkA signaling mediates the proliferation, differentiation, and survival of neurons and other cells following stimulation by its ligand, the nerve growth factor. Chromosomal rearrangements of the NTRK1 gene result in the generation of TrkA fusion protein, which is known to cause deregulation of TrkA signaling. Targeting TrkA activity represents a promising strategy for the treatment of cancers that harbor the TrkA fusion protein. In this study, we evaluated the TrkA-inhibitory activity of the benzoxazole compound KRC-108. KRC-108 inhibited TrkA activity in an in vitro kinase assay, and suppressed the growth of KM12C colon cancer cells harboring an NTRK1 gene fusion. KRC-108 treatment induced cell cycle arrest, apoptotic cell death, and autophagy. KRC-108 suppressed the phosphorylation of downstream signaling molecules of TrkA, including Akt, phospholipase Cγ, and ERK1/2. Furthermore, KRC-108 exhibited antitumor activity in vivo in a KM12C cell xenograft model. These results indicate that KRC-108 may be a promising therapeutic agent for Trk fusion-positive cancers.
Keywords
Tropomyosin receptor kinase A; Neurotrophic receptor kinase 1 fusion; KRC-108; Colon cancer;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Cho, S. Y., Han, S. Y., Ha, J. D., Ryu, J. W., Lee, C. O., Jung, H., Kang, N. S., Kim, H. R., Koh, J. S. and Lee, J. (2010) Discovery of aminopyridines substituted with benzoxazole as orally active c-Met kinase inhibitors. Bioorg. Med. Chem. Lett. 20, 4223-4227.   DOI
2 Cocco, E., Scaltriti, M. and Drilon, A. (2018) NTRK fusion-positive cancers and TRK inhibitor therapy. Nat. Rev. Clin. Oncol. 15, 731-747.   DOI
3 Doebele, R. C., Davis, L. E., Vaishnavi, A., Le, A. T., Estrada-Bernal, A., Keysar, S., Jimeno, A., Varella-Garcia, M., Aisner, D. L., Li, Y., Stephens, P. J., Morosini, D., Tuch, B. B., Fernandes, M., Nanda, N. and Low, J. A. (2015) An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discov. 5, 1049-1057.   DOI
4 Han, S. Y. (2021) TRK Inhibitors: tissue-agnostic anti-cancer drugs. Pharmaceuticals (Basel) 14, 632.   DOI
5 Jorgensen, J. T. (2020) Site-agnostic biomarker-guided oncology drug development. Expert Rev. Mol. Diagn. 20, 583-592.   DOI
6 Franke, T. F., Hornik, C. P., Segev, L., Shostak, G. A. and Sugimoto, C. (2003) PI3K/Akt and apoptosis: size matters. Oncogene 22, 8983-8998.   DOI
7 Ardini, E., Menichincheri, M., Banfi, P., Bosotti, R., De Ponti, C., Pulci, R., Ballinari, D., Ciomei, M., Texido, G., Degrassi, A., Avanzi, N., Amboldi, N., Saccardo, M. B., Casero, D., Orsini, P., Bandiera, T., Mologni, L., Anderson, D., Wei, G., Harris, J., Vernier, J. M., Li, G., Felder, E., Donati, D., Isacchi, A., Pesenti, E., Magnaghi, P. and Galvani, A. (2016) Entrectinib, a Pan-TRK, ROS1, and ALK inhibitor with activity in multiple molecularly defined cancer indications. Mol. Cancer Ther. 15, 628-639.   DOI
8 Harada, G., Gongora, A. B. L., da Costa, C. M. and Santini, F. C. (2020) TRK inhibitors in non-small cell lung cancer. Curr. Treat. Options Oncol. 21, 39.   DOI
9 Khotskaya, Y. B., Holla, V. R., Farago, A. F., Mills Shaw, K. R., MericBernstam, F. and Hong, D. S. (2017) Targeting TRK family proteins in cancer. Pharmacol. Ther. 173, 58-66.   DOI
10 Doebele, R. C., Drilon, A., Paz-Ares, L., Siena, S., Shaw, A. T., Farago, A. F., Blakely, C. M., Seto, T., Cho, B. C., Tosi, D., Besse, B., Chawla, S. P., Bazhenova, L., Krauss, J. C., Chae, Y. K., Barve, M., Garrido-Laguna, I., Liu, S. V., Conkling, P., John, T., Fakih, M., Sigal, D., Loong, H. H., Buchschacher, G. L., Jr., Garrido, P., Nieva, J., Steuer, C., Overbeck, T. R., Bowles, D. W., Fox, E., Riehl, T., Chow-Maneval, E., Simmons, B., Cui, N., Johnson, A., Eng, S., Wilson, T. R. and Demetri, G. D.; trial investigators (2020) Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 21, 271-282.   DOI
11 Onorati, A. V., Dyczynski, M., Ojha, R. and Amaravadi, R. K. (2018) Targeting autophagy in cancer. Cancer 124, 3307-3318.   DOI
12 Medico, E., Russo, M., Picco, G., Cancelliere, C., Valtorta, E., Corti, G., Buscarino, M., Isella, C., Lamba, S., Martinoglio, B., Veronese, S., Siena, S., Sartore-Bianchi, A., Beccuti, M., Mottolese, M., Linnebacher, M., Cordero, F., Di Nicolantonio, F. and Bardelli, A. (2015) The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nat. Commun. 6, 7002.   DOI
13 Han, S. Y., Lee, C. O., Ahn, S. H., Lee, M. O., Kang, S. Y., Cha, H. J., Cho, S. Y., Ha, J. D., Ryu, J. W., Jung, H., Kim, H. R., Koh, J. S. and Lee, J. (2012) Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo. Invest. New Drugs 30, 518-523.   DOI
14 Hansen, K., Wagner, B., Hamel, W., Schweizer, M., Haag, F., Westphal, M. and Lamszus, K. (2007) Autophagic cell death induced by TrkA receptor activation in human glioblastoma cells. J. Neurochem. 103, 259-275.   DOI
15 Hirose, M., Kuroda, Y. and Murata, E. (2016) NGF/TrkA signaling as a therapeutic target for pain. Pain Pract. 16, 175-182.   DOI
16 Kondo, Y., Kanzawa, T., Sawaya, R. and Kondo, S. (2005) The role of autophagy in cancer development and response to therapy. Nat. Rev. Cancer 5, 726-734.   DOI
17 Levy, J. M. M., Towers, C. G. and Thorburn, A. (2017) Targeting autophagy in cancer. Nat. Rev. Cancer 17, 528-542.   DOI
18 Al-Salama, Z. T. and Keam, S. J. (2019) Entrectinib: first global approval. Drugs 79, 1477-1483.   DOI
19 Menichincheri, M., Ardini, E., Magnaghi, P., Avanzi, N., Banfi, P., Bossi, R., Buffa, L., Canevari, G., Ceriani, L., Colombo, M., Corti, L., Donati, D., Fasolini, M., Felder, E., Fiorelli, C., Fiorentini, F., Galvani, A., Isacchi, A., Borgia, A. L., Marchionni, C., Nesi, M., Orrenius, C., Panzeri, A., Pesenti, E., Rusconi, L., Saccardo, M. B., Vanotti, E., Perrone, E. and Orsini, P. (2016) Discovery of entrectinib: a new 3-aminoindazole as a potent anaplastic lymphoma kinase (ALK), c-ros oncogene 1 kinase (ROS1), and pan-tropomyosin receptor kinases (pan-TRKs) inhibitor. J. Med. Chem. 59, 3392-3408.   DOI
20 Okamura, R., Boichard, A., Kato, S., Sicklick, J. K., Bazhenova, L. and Kurzrock, R. (2018) Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics. JCO Precis. Oncol. 2018, PO.18.00183.
21 Bongarzone, I., Pierotti, M. A., Monzini, N., Mondellini, P., Manenti, G., Donghi, R., Pilotti, S., Grieco, M., Santoro, M. and Fusco, A. (1989) High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene 4, 1457-1462.
22 Martin-Zanca, D., Hughes, S.H. and Barbacid, M. (1986) A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature 319, 743-748.   DOI
23 Noh, H. S., Hah, Y. S., Zada, S., Ha, J. H., Sim, G., Hwang, J. S., Lai, T. H., Nguyen, H. Q., Park, J. Y., Kim, H. J., Byun, J. H., Hahm, J. R., Kang, K. R. and Kim, D. R. (2016) PEBP1, a RAF kinase inhibitory protein, negatively regulates starvation-induced autophagy by direct interaction with LC3. Autophagy 12, 2183-2196.   DOI
24 Pan, H., Wang, Z., Jiang, L., Sui, X., You, L., Shou, J., Jing, Z., Xie, J., Ge, W., Cai, X., Huang, W. and Han, W. (2014) Autophagy inhibition sensitizes hepatocellular carcinoma to the multikinase inhibitor linifanib. Sci. Rep. 4, 6683.   DOI
25 Dadakhujaev, S., Jung, E. J., Noh, H. S., Hah, Y. S., Kim, C. J. and Kim, D. R. (2009) Interplay between autophagy and apoptosis in TrkA-induced cell death. Autophagy 5, 103-105.   DOI
26 Cagnol, S. and Chambard, J.-C. (2010) ERK and cell death: mechanisms of ERK-induced cell death - apoptosis, autophagy and senescence. FEBS J. 277, 2-21.   DOI
27 Chou, T. C. and Talalay, P. (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22, 27-55.   DOI
28 Ardini, E., Bosotti, R., Borgia, A. L., De Ponti, C., Somaschini, A., Cammarota, R., Amboldi, N., Raddrizzani, L., Milani, A., Magnaghi, P., Ballinari, D., Casero, D., Gasparri, F., Banfi, P., Avanzi, N., Saccardo, M. B., Alzani, R., Bandiera, T., Felder, E., Donati, D., Pesenti, E., Sartore-Bianchi, A., Gambacorta, M., Pierotti, M. A., Siena, S., Veronese, S., Galvani, A. and Isacchi, A. (2014) The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol. Oncol. 8, 1495-1507.   DOI
29 Reichardt, L. F. (2006) Neurotrophin-regulated signalling pathways. Philos. Trans. R. Soc. Lond. B Biol. Sci. 361, 1545-1564.   DOI
30 Scott, L. J. (2019) Larotrectinib: first global approval. Drugs 79, 201-206.   DOI
31 Chung, H. J., Park, K. R., Lee, H. J., Lee, J., Kim, J. H., Kim, Y. C. and Han, S. Y. (2015) Effects of KRC-108 on the Aurora A activity and growth of colorectal cancer cells. Biochem. Biophys. Res. Commun. 461, 605-611.   DOI
32 Dadakhujaev, S., Noh, H. S., Jung, E. J., Hah, Y.-S., Kim, C. J. and Kim, D. R. (2008) The reduced catalase expression in TrkA-induced cells leads to autophagic cell death via ROS accumulation. Exp. Cell Res. 314, 3094-3106.   DOI